

10th December 2025

- | | |
|---|---|
| <p>(1) BSE Ltd
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001
Scrip Code: 500087</p> | <p>(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051
Scrip Code: CIPLA EQ</p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg</p> | |

Dear Sir / Madam,

Sub: Update on launch of Yurpeak® (Tirzepatide) in India for the treatment of Obesity and Type 2 Diabetes

Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and further to our intimation dated 23rd October 2025, we hereby notify the launch of Yurpeak® (Tirzepatide) under the marketing and distribution agreement executed between the Company and Eli Lilly and Company (India) Private Limited.

A press release on the above mentioned subject is enclosed herewith.

Please take the above information on record.

Yours faithfully,
For Cipla Limited

Rajendra Chopra
Company Secretary

Prepared by: Chirag Hotchandani

Encl: a/a

Cipla launches Yurpeak® (tirzepatide) for the treatment of Obesity and Type 2 Diabetes

- Yurpeak® is a prescription medicine and should be used under medical advice
- Will be available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg strengths

Mumbai, December 10, 2025: Cipla Limited (BSE: 500087; NSE: CIPLA; and hereafter referred to as "Cipla") today announced the launch of Yurpeak® (tirzepatide), a one-weekly injectable therapy for managing obesity and type 2 diabetes mellitus (T2DM) — two of the country's most pressing health challenges. Cipla has the rights to distribute and promote Yurpeak® — the second brand of Lilly's tirzepatide in India, after Lilly received DCGI approval.

Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, indicated as an adjunct to diet and exercise for the treatment of Type 2 diabetes and Chronic weight management in adults with obesity (BMI \geq 30) or overweight (BMI \geq 27) with at least one weight-related comorbidity.

Yurpeak® will be available on prescription in the KwikPen® device format in six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, allowing for precise, convenient, and patient-friendly dosing.

Commenting on the launch, **Achin Gupta, Global Chief Operating Officer, Cipla Limited, said:** *"The launch of Yurpeak® marks a transformative moment in the fight against obesity and type 2 diabetes mellitus, two of India's chronic conditions with a heavy burden. Cipla is entering this space with the same depth of expertise and scientific commitment that define our leadership in chronic diseases and in respiratory care. Our focus remains on accelerating access to globally benchmarked, future-ready therapies through collaborations like ours with Lilly, which bring together innovation, purpose, and scale to ensure advanced care reaches patients wherever they are."*

Launch of Yurpeak® in India will help expand access to tirzepatide so that more patients can benefit from this innovative therapy. Cipla's strategic priority is to make it available across India, including regions beyond metro cities, leveraging its strong distribution network and deep market insights to drive greater nationwide reach and accessibility. Lilly will manufacture and supply Yurpeak® to Cipla, and the price will be the same as Mounjaro®.

Cipla will complement the launch of Yurpeak® with comprehensive patient education and support programs, including guidance on dosing, self-administration, and safe, informed use of the therapy. These initiatives are designed to help patients navigate their treatment confidently and responsibly, in consultation with their healthcare professionals. This approach is backed by Cipla's long-standing commitment to evidence-based communication and responsible care, empowering individuals to make timely health decisions and adopt sustainable wellness practices.

About Cipla

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Sep'25), 2nd Largest in the pharma prescription market in South Africa (IQVIA MAT Aug'25), and 4th largest by prescription in the US Gx (Repulses + MDI) products (IQVIA MAT Aug'25). For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit www.cipla.com, or click on [Twitter](#), [Facebook](#), [LinkedIn](#).

For queries, please contact:

Corporate Communications
Heena Kanal
E-Mail: CorpComm@cipla.com

Investor Relations
Diksha Maheshwari
E-Mail: Investor.Relations@cipla.com